Melanotan I

What it is

Melanotan I, also called afamelanotide, is a 13-amino-acid analog of a natural hormone that controls skin pigment. A chemical tweak makes it resist breakdown, so it acts longer. It won FDA approval in 2019 as Scenesse for a rare, painful light-intolerance disorder called erythropoietic protoporphyria, or EPP.

How it works

It activates a receptor called MC1R on pigment cells, which responds by churning out the dark skin pigment eumelanin. That pigment darkens skin without needing ultraviolet light. For EPP patients, the extra pigment lets them tolerate sunlight without searing, porphyrin-driven pain. For cosmetic users, it produces visible tanning over weeks.

What people report

• ✦Transformed life for EPP patients who could barely tolerate sunlight
• ✦Produces reliable, UV-independent tanning over 2–6 weeks
• ✦Selective for MC1R, so a cleaner profile than its sibling melanotan II: less nausea, no sexual-arousal effect
• ✦A 2025 phase 3 trial in vitiligo finished enrollment, with results expected soon

Typical use

The approved product is a 16 mg controlled-release implant placed by a dermatologist roughly every two months. It is not a daily shot. Cosmetic users inject far smaller subcutaneous doses, an unstudied schedule.

Dosing reference

The only validated dosing is the approved 16 mg implant, which costs on the order of $49,000 per implant and is placed by a physician. The gray-market vial is a completely different route with no established dosing. Verify accordingly.

Reference only — not a recommendation. Verify via primary sources.

Watch for

Notes

Chemistry is strong and the approved safety record is reassuring, but that record does not transfer cleanly to how people casually dose the gray-market version.